Increasing the use of microphysiological systems (MPS) in Three Rs and regulatory applications is a nuanced but important goal, which would also help increase their scientific impact. There are three distinct and important stakeholder groups that each play a unique role in expediting the use of MPS for regulatory purpose — namely, commercial MPS developers, end-users and regulators. Additionally, non-profit organisations, such as the 3Rs Collaborative (3RsC), can help coordinate these efforts. This paper introduces the MPS Initiative, as organised by the 3RsC, and clarifies the potential for MPS to benefit all Three Rs. Key differences in the use of MPS-derived data for regulatory evidence of efficacy versus safety, and for various other contexts of use, are discussed. Finally, the results are presented from a survey of primarily commercial MPS developers, that collected their views on the realistic responsibilities of each stakeholder group. The results also highlight their key perspectives on the use of MPS, in the context of Three Rs and regulatory applications.
BaranSWBrownPCBaudyAR, et al. Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). ALTEX2022; 39: 297–314.
2.
RussellWMSBurchRL. The principles of humane experimental technique. London: Methuen, 1959, p. 238 + xiv pp.
3.
TannenbaumJBennettBT. Russell and Burch’s 3Rs then and now: The need for clarity in definition and purpose. J Am Assoc Lab Anim Sci2015; 54: 120–132.
4.
MacArthurClark J. The 3Rs in research: A contemporary approach to replacement, reduction and refinement. Br J Nutr2018; 120(S1): S1–S7.
5.
ParkerRMABrowneWJ. The place of experimental design and statistics in the 3Rs. ILAR J2014; 55: 477–485.
6.
RobinsonV.Finding alternatives: An overview of the 3Rs and the use of animals in research. School Sci Rev2005; 87: 111–114.
7.
FabreKBerridgeBProctorWR, et al.Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip2020; 20: 1049–1057.
8.
MarxUAkabaneTAnderssonTB, et al.Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX2020; 37: 365–394.
9.
YeWChenQ. Potential applications and perspectives of humanized mouse models. Annu Rev Anim Biosci2022; 10: 395–417.
10.
AllenTMBrehmMABridgesS, et al.Humanized immune system mouse models: Progress, challenges and opportunities. Nat Immunol2019; 20: 770–774.
11.
ChuprinJBuettnerHSeedhomMO, et al.Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol2023; 20: 192–206.
12.
IrrechukwuOYeagerRDavidR, et al.Applications of microphysiological systems to disease models in the biopharmaceutical industry: Opportunities and challenges. ALTEX2023; 40: 485–518.
13.
WeaverJLWuWHylandPL, et al.Expanding approved patient populations for rare disease treatment using in vitro data. Clin Pharmacol Ther2022; 112: 58–61.
14.
TurnerJPoundPOwenC, et al.Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment. ALTEX2023; 40: 519–533.
15.
AhmedSSWangXNFieldingM, et al.An in vitro human skin test for assessing sensitization potential. J Appl Toxicol2016; 36: 669–684.
16.
AhmedSSWhritenourJAhmedMM, et al.Evaluation of a human in vitro skin test for predicting drug hypersensitivity reactions. Toxicol Appl Pharmacol2019; 369: 39–48.
17.
WangXKopecAKCollingeM, et al.Application of immunocompetent microphysiological systems in drug development: Current perspective and recommendations. ALTEX2022; 40: 314–336.
18.
Marrer-BergerENicastriAAugustinA, et al.The physiological interactome of TCR-like antibody therapeutics in human tissues. Nat Commun2024; 15: 3271.
19.
RibeiroAJSYangXPatelV, et al.Liver microphysiological systems for predicting and evaluating drug effects. Clin Pharmacol Ther2019; 106: 139–147.
Non-clinical Working Party. Consolidated 3-year work plan for the non-clinical domain including the priorities for 2023, Report No.: EMA/CHMP/14829/2023. Amsterdam: European Medicines Agency, 2023.
22.
van der ZalmAJBarrosoJBrowneP, et al.A framework for establishing scientific confidence in new approach methodologies. Arch Toxicol2022; 96: 2865–2879.
MoisanAKoleskyDMillerJ, et al.Translation of tissue-engineering innovations requires a connected ecosystem. Nat Rev Bioeng2023; 1: 879–881.
25.
CandarliogluPLDalNGHughesD, et al.Organ-on-a-chip: Current gaps and future directions. Biochem Soc Trans2022; 50: 665–673.
26.
RusynISakolishCKatoY, et al.Microphysiological systems evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium. Toxicol Sci2022; 188: 143–152.
27.
ThomasRSBahadoriTBuckleyTJ, et al.The next generation blueprint of computational toxicology at the US Environmental Protection Agency. Toxicol Sci2019; 169: 317–332.
28.
AjzenI. The theory of planned behavior. Organ Behav Hum Decis Process1991; 50: 179–211.
29.
AvilaAMBebenekIMendrickDL, et al.Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies. Regul Toxicol Pharmacol2023; 139: 105345.
GambleJTHopperstadKDeisenrothC. The DevTox germ layer reporter platform: An assay adaptation of the human pluripotent stem cell test. Toxics2022; 10: 392.
32.
DeisenrothCSoldatowVYFordJ, et al.Development of an in vitro human thyroid microtissue model for chemical screening. Toxicol Sci2020; 174: 63–78.
33.
FaberSCMcNabbNAArielP, et al.Exposure effects beyond the epithelial barrier: Transepithelial induction of oxidative stress by diesel exhaust particulates in lung fibroblasts in an organotypic human airway model. Toxicol Sci2020; 177: 140–155.
KuemmelCYangYZhangX, et al.Consideration of a credibility assessment framework in model-informed drug development: Potential application to physiologically-based pharmacokinetic modeling and simulation. CPT Pharmacometrics Syst Pharmacol2020; 9: 21–28.
36.
AvilaAMBebenekIBonzoJA, et al.An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol2020; 114: 104662.
37.
AinslieGRDavisMEwartL, et al.Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: A biopharmaceutical perspective. Lab Chip2019; 19: 3152–3161.
38.
HardwickRNBettsCJWhritenourJ, et al. Drug-induced skin toxicity: Gaps in preclinical testing cascade as opportunities for complex in vitro models and assays. Lab Chip2020; 20: 199–214.
39.
BaudyAROtienoMAHewittP, et al.Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab Chip2020; 20: 215–225.
40.
PhillipsJAGrandhiTSPDavisM, et al.A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies. Lab Chip2020; 20: 468–476.
41.
FowlerSChenWLKDuignanDB, et al.Microphysiological systems for ADME-related applications: Current status and recommendations for system development and characterization. Lab Chip2020; 20: 446–467.
42.
PetersonNCMahalingaiahPKFullertonA, et al.Application of microphysiological systems in biopharmaceutical research and development. Lab Chip2020; 20: 697–708.
43.
PetersMFChoyALPinC, et al.Developing in vitro assays to transform gastrointestinal safety assessment: Potential for microphysiological systems. Lab Chip2020; 20: 1177–1190.
44.
PointonAMaherJDavisM, et al.Cardiovascular microphysiological systems (CVMPS) for safety studies — a pharma perspective. Lab Chip2021; 21: 458–472.
45.
RamsdenDBelairDGAgarwalS, et al.Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics. ALTEX2022; 39: 273–296.
46.
TomlinsonLRamsdenDLeiteSB, et al.Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) workshop on the standardization of complex in vitro models in drug development. Adv Biol2024; 8: e2300131.
47.
DebadSAllenDBandeleO, et al.Trust your gut: Establishing confidence in gastrointestinal models — An overview of the state of the science and contexts of use. ALTEX2024; 41: 402–424.
48.
ReyesDREschMBEwartL, et al.From animal testing to in vitro systems: Advancing standardization in microphysiological systems. Lab Chip2024; 24: 1076–1087.
49.
PamiesDEkertJZurichMG, et al.Recommendations on fit-for-purpose criteria to establish quality management for microphysiological systems and for monitoring their reproducibility. Stem Cell Reports2024; 19: 604–617.
50.
OECD. Guidance Document on Good In Vitro Method Practices (GIVIMP). OECD Series on Testing and Assessment, No. 286. Paris: OECD Publishing, 2018, 206 pp.
PulsoniILubdaMAielloM, et al.Comparison between Franz diffusion cell and a novel micro-physiological system for in vitro penetration assay using different skin models. SLAS Technol2022; 27: 161–171.
53.
RubianoAIndapurkarAYokosawaR, et al.Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. Clin Transl Sci2021; 14: 1049–1061.
54.
WangQCohenJDYukawaT, et al.Assessment of a 3D neural spheroid model to detect pharmaceutical-induced neurotoxicity. ALTEX2022; 39: 560–582.
55.
EwartLApostolouABriggsSA, et al.Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun Med2022; 2: 1–16.
56.
StuckiAOSauerUGAllenDG, et al.Differences in the anatomy and physiology of the human and rat respiratory tracts and impact on toxicological assessments. Regul Toxicol Pharmacol2024; 150: 105648.
OECD. Test No. 428: Skin absorption: In vitro method, OECD Guidelines for the Testing of Chemicals, Section 4. Paris: Organisation for Economic Co-operation and Development, 2004, 8 pp.
59.
OECD. Test No. 427: Skin absorption: In vivo method, OECD Guidelines for the Testing of Chemicals, Section 4. Paris: Organisation for Economic Co-operation and Developerment, 2004, 8 pp.
60.
AllenDGRooneyJKleinstreuerN, et al.Retrospective analysis of dermal absorption triple pack data. ALTEX2021; 38: 463–476.
MitraAKimNSparkD, et al.Use of an in vitro human skin permeation assay to assess bioequivalence of two topical cream formulations containing butenafine hydrochloride (1%, w/w). Regul Toxicol Pharmacol2016; 82: 14–19.
63.
MadenMVarholickJA. Model systems for regeneration: The spiny mouse, Acomys cahirinus. Development2020; 147: dev167718.
